$27.92 +0.50 (%) Anacor Pharmaceuticals Inc - NASDAQ

Oct. 21, 2014 | 10:20 AM

Partner Headlines

  1. Stocks Hitting 52-Week Highs

    Benzinga | Oct. 20, 2014 | 10:08AM EST
  2. Anacor Pharmaceuticals, Inc. Announces Proposed Offering of $70M Of Convertible Senior Notes Due 2021

    Benzinga | Oct. 8, 2014 | 16:01PM EST
  3. Paulson Bets Again On Mallinckrodt

    GuruFocus | Aug. 7, 2014 | 11:02AM EST
  4. Benzinga's Volume Movers

    Benzinga | Jul. 21, 2014 | 10:31AM EST
  5. Anacor Pharmaceuticals And Sandoz Enter Into An Agreement For The Commercialization Of KERYDIN In The United States

    Benzinga | Jul. 21, 2014 | 07:03AM EST
  6. 5-Star Biotech Stock Watch: Anacor Pharmaceuticals

    Benzinga | Jul. 2, 2014 | 11:09AM EST
  7. Mid-Afternoon Market Update: Markets Go Red as Anadarko Rallies on Settlement with US

    Benzinga | Apr. 3, 2014 | 15:45PM EST
  8. Mid-Day Market Update: US Stocks Fall; Google Shares Rise After Stock Split

    Benzinga | Apr. 3, 2014 | 12:41PM EST
  9. US Stock Futures Up Ahead Of Chicago PMI

    Benzinga | Mar. 31, 2014 | 07:31AM EST
  10. Earnings Scheduled For March 13, 2014

    Benzinga | Mar. 13, 2014 | 04:51AM EST
  11. Anacor Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA for the Treatment of Mild-to-Moderate Atopic Dermatitis With AN2728

    Benzinga | Feb. 27, 2014 | 07:32AM EST
  12. Valeant Pharmaceuticals

    IBD | Oct. 28, 2013 | 18:52PM EST
  13. Anacor Pharmaceuticals Awarded $13.5M in Research Agreement with Defense Threat Reduction Agency

    Benzinga | Oct. 21, 2013 | 09:14AM EST
  14. Benzinga's Top Pre-Market Gainers

    Benzinga | Oct. 18, 2013 | 08:07AM EST
  15. Anacor Pharmaceuticals Announces Award of $100M in Arbitration with Valeant

    Benzinga | Oct. 17, 2013 | 23:29PM EST
  16. These Three Speculative Companies Are Loved By Insiders and Institutions

    Benzinga | Aug. 22, 2013 | 11:55AM EST
  17. Weekly CFO Buys Highlight

    GuruFocus | Aug. 19, 2013 | 13:32PM EST
  18. 3 Great Dividend Stocks at All-Time Highs

    GuruFocus | Aug. 19, 2013 | 13:31PM EST
  19. Stocks Hitting 52-Week Highs

    Benzinga | Aug. 14, 2013 | 10:40AM EST
  20. Stocks Hitting 52-Week Lows

    Benzinga | Feb. 11, 2013 | 03:32AM EST
  21. Stocks Hitting 52-Week Lows

    Benzinga | Jan. 29, 2013 | 03:30AM EST
  22. A Peek Into The Market Before The Trading Starts

    Benzinga | Jan. 29, 2013 | 00:22AM EST
  23. Anacor Pharmaceuticals Announces Positive Phase 3 Trial Results for Tavaborole for Onychomycosis

    Benzinga | Jan. 29, 2013 | 00:05AM EST
  24. Anacor Pharmaceuticals Announces Positive Results From Phase 2 Trial of AN2728

    Benzinga | Dec. 10, 2012 | 09:01AM EST
  25. Anacor Pharmaceuticals Inc Reports Operating Results (10-Q)

    GuruFocus | Nov. 9, 2012 | 11:36AM EST
  26. Anacor Pharmaceuticals Prices $24 Million Public Offering of Common Stock

    Benzinga | Oct. 18, 2012 | 03:01AM EST
  27. Anacor Pharmaceuticals Announces That GSK Has Discontinued Clinical Development of GSK2251052

    Benzinga | Oct. 5, 2012 | 02:32AM EST
  28. (ANAC) CFO Geoffrey M. Parker buys 5,000 Shares

    GuruFocus | Aug. 24, 2012 | 12:23PM EST
  29. Health Care Sector Wrap

    FoxBusiness | Aug. 16, 2012 | 10:45AM EST
  30. (ANAC) CFO Geoffrey M. Parker buys 7,954 Shares

    GuruFocus | Jun. 5, 2012 | 16:22PM EST
  31. Anacor Pharmaceuticals Appoints Paul L. Berns to Its Board of Directors

    Benzinga | Jun. 1, 2012 | 10:02AM EST
  32. Earnings Scheduled For March 5

    Benzinga | Mar. 4, 2012 | 21:11PM EST
  33. Anacor Pharmaceuticals Announces the Sale of 3.25 Million Shares of Common Stock

    Benzinga | Feb. 8, 2012 | 09:20AM EST
  34. Anacor Pharmaceuticals Announces Positive Preliminary Results from Two Safety Studies of AN2728 and Updates Atopic Dermatitis Results and Regulatory Status

    Benzinga | Feb. 7, 2012 | 01:32AM EST
  35. Anacor Pharmaceuticals Down 14.4% After GlaxoSmithKline Pauses Ongoing Trials

    Benzinga | Feb. 6, 2012 | 02:20AM EST
  36. Stocks To Watch For December 28

    Benzinga | Dec. 27, 2011 | 19:28PM EST
  37. Anacor Pharma Registers To Offer Up To $50M In Mixed Securities

    Benzinga | Dec. 27, 2011 | 09:02AM EST
  38. Wedbush Maintains Outperform, $13 Target on Anacor

    Benzinga | Dec. 13, 2011 | 02:44AM EST
Trading Center